T, B, & NK cells and Stem cell scientist for 50 yrs , Commercialized CD4/IL-2r, CD34 Mabs at BDMC &ABI TaqMan mRNA Gene Expression during human genome project.
Dr. Prasad, can you comment on DCVax-Direct? No AI needed.
Your own numbers frame it. You estimated that genome-targeted therapy benefits about 5% of patients with advanced cancer, and that one in five responds to a checkpoint inhibitor. The first needs a mutation to aim at. The second needs T cells already in the tumor.
DCVax-Direct needs neither. Activated dendritic cells go straight into the tumor and collect the antigens themselves. No sequencing, no algorithm, no target to choose.
The MD Anderson Phase 1, 40 patients with advanced solid tumors: no dose-limiting toxicity. T cells moved into the tumor in 54% of biopsied patients. PD-L1 was newly induced or increased in 19 of 25 tumors, the pathway Keytruda blocks. The cells' cytokine output, measured before injection, predicted who stabilized and who lived longer. The authors wrote that these cells "lead to stabilization of disease, resulting in prolonged survival."
Checkpoint drugs fail in tumors with no T cells. This put T cells there. Published 2018. Phase 2 never run.
Thank you for the plausible mechanism work. Here is the mechanism. Run the trial.
Dendritic cells do bioinformatics for a living.
🎄🎁 LET’S MAKE THIS THE BIGGEST YEAR YET!
Today, Braelyn and I are delivering neighborhood flyers for her 4TH ANNUAL CHRISTMAS TOY DRIVE benefiting Prisma Health Children’s Hospital! ❤️
Inspired by her own hospitalization at age 16, Braelyn started this tradition in 2023 to bring Christmas joy to other hospitalized children.
Since then, she’s collected and delivered THOUSANDS of toys and gifts!
Donations have already started arriving, and we’re incredibly grateful! ❤️
Now it’s time to kick things into HIGH GEAR!
🎁 Toys, games, books, personal items, PJ’s, & gifts for babies through teens!
📅 Deadline: DECEMBER 11
📬 Wish list and mailing details in the flyer!
Please donate if you can, SHARE, and help us make Braelyn’s 4th annual toy drive her BIGGEST YET!
Every child deserves a little Christmas magic. 🎄❤️
Mail to:
Braelyn Hollensbe
PO Box 7
Clemson, SC 29631
$NWBO | 𝗗𝗖𝗩𝗮𝘅 𝗔𝗡𝗗 𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗗𝗘𝗖𝗜𝗦𝗜𝗢𝗡 𝗜𝗡 𝗚𝗟𝗜𝗢𝗕𝗟𝗔𝗦𝗧𝗢𝗠𝗔
Personalization should continue after the vaccine is made.
Peter's post highlights the shift toward biomarker-guided combinations. For DCVax, the key is to follow three things together: what the prepared cells can do, whether the patient develops tumor-directed immunity, and whether the cancer is controlled.
The deeper question is durability: does treatment establish an immune capability that persists after dosing ends?
The full analysis connects vaccine preparation, endogenous dendritic-cell feedback, functional memory and host support into a testable development strategy. Each measurement helps identify the next problem to solve.
The companion video opens the article.
#DCVax #DCVaxForBraelyn #Glioblastoma #GBM #CancerImmunotherapy
https://t.co/42aENlhhle
The transcript repeatedly misspells it due to speech-to-text errors. The real scientist is Andy/Andrew Blidy (@ablidy), co-author of the 2026 Immune Teeter-Totter work and the 1990 CD25/PE discovery.
Quick explanation of the transcript
This is a deep dive into the March 2026 archival document The Immune Teeter-Totter. Its core claim is that cancer and autoimmunity are not separate fields. They are opposite sides of the same biological axis controlled by dendritic cell polarity.
One automated machine (Eden Chassis) can be loaded with different chemical “software” (maturation cocktails).
Immunogenic mode (αDC1: TNF-α, IL-1β, IFN-γ, IFN-α, polyI:C) → high IL-12p70 → trains high-avidity killer T cells and NK cells to attack tumors (e.g., glioblastoma).
Tolerogenic mode (vitamin D3 + IL-10) → epigenetic remodeling via VDR/STAT3/TET2 → produces IL-10 and induces specific auto-reactive T cells to die, useful for autoimmunity or transplant tolerance.
Historical root: Andy Blidy’s 1990 work at BDMC. Using brighter PE-conjugated antibodies (20× higher quantum yield than FITC), his team showed ~31% of resting healthy CD4+ memory T cells constitutively express CD25. That population became the regulatory T cells (Tregs) later linked to the 2018 (checkpoint blockade) and 2025 (Tregs/FOXP3) Nobel Prizes.
Critical rules: Instruction (properly polarized dendritic cells) must come before optimization (checkpoint inhibitors). Metabolism writes chromatin, locking the chosen polarity into epigenetic memory.
Same platform theoretically maps to 21 diseases and even longevity (clearing senescent cells).
Cartoon showing memory (epigenetic + immune)
📷📷
These cartoons visualize the key “memory” idea from the transcript: the polarity is locked into lasting epigenetic memory so the immune system remembers whether to attack or tolerate.
The transcript repeatedly misspells it due to speech-to-text errors. The real scientist is Andy/Andrew Blidy (@ablidy), co-author of the 2026 Immune Teeter-Totter work and the 1990 CD25/PE discovery.
Quick explanation of the transcript
This is a deep dive into the March 2026 archival document The Immune Teeter-Totter. Its core claim is that cancer and autoimmunity are not separate fields. They are opposite sides of the same biological axis controlled by dendritic cell polarity.
One automated machine (Eden Chassis) can be loaded with different chemical “software” (maturation cocktails).
Immunogenic mode (αDC1: TNF-α, IL-1β, IFN-γ, IFN-α, polyI:C) → high IL-12p70 → trains high-avidity killer T cells and NK cells to attack tumors (e.g., glioblastoma).
Tolerogenic mode (vitamin D3 + IL-10) → epigenetic remodeling via VDR/STAT3/TET2 → produces IL-10 and induces specific auto-reactive T cells to die, useful for autoimmunity or transplant tolerance.
Historical root: Andy Blidy’s 1990 work at BDMC. Using brighter PE-conjugated antibodies (20× higher quantum yield than FITC), his team showed ~31% of resting healthy CD4+ memory T cells constitutively express CD25. That population became the regulatory T cells (Tregs) later linked to the 2018 (checkpoint blockade) and 2025 (Tregs/FOXP3) Nobel Prizes.
Critical rules: Instruction (properly polarized dendritic cells) must come before optimization (checkpoint inhibitors). Metabolism writes chromatin, locking the chosen polarity into epigenetic memory.
Same platform theoretically maps to 21 diseases and even longevity (clearing senescent cells).
Cartoon showing memory (epigenetic + immune)
📷📷
These cartoons visualize the key “memory” idea from the transcript: the polarity is locked into lasting epigenetic memory so the immune system remembers whether to attack or tolerate.
Going deeper, because the most useful result in that paper is one the authors treat as a footnote.
Start with what a dendritic cell actually has to do.
It swallows debris from a dead tumor cell into a small bag inside itself. Whatever stays in that bag gets shown to helper T cells. Helpers are useful. Helpers do not kill anything.
To make killers, the contents of the bag have to get out of the bag and into the body of the cell. That is the whole game, and it is a physical problem, not a chemical one.
CLEC9A solves it by bursting the bag. The receptor fires, SYK switches on an enzyme that floods the compartment, and the bag ruptures from the inside. Tumor protein spills into the cell, where the killer-cell display system is waiting.
That rupture is cross-presentation. No rupture, no killers.
Now look at what they did to it.
They rebuilt the receptor with its signaling parts disabled. It still binds the tumor. It still sits exactly where it should. It does nothing.
Grabbing is not teaching. Two different events, and only one of them matters.
They knocked out SYK and cross-presentation collapsed. They blocked SYK with a drug, same result. They knocked out the adapter that DEC205 has to borrow in order to reach SYK, because DEC205 has no signaling tail of its own, and that arm died too.
Every road ran through the same switch.
Then the part nobody is discussing.
What flips that switch in nature is not a tumor marker. It is actin, the scaffolding inside every living cell, which only becomes visible when a membrane breaks open.
CLEC9A is not a tumor sensor. It is a corpse sensor. Its job is to notice that something died here and find out what it was.
Autologous tumor lysate is a tumor corpse.
A lysate-loaded dendritic cell is not waiting to be handed a signal. It arrived holding it.
And this is the part that matters more than it sounds. A tumor can delete a surface protein. Tumors do it constantly. It is the main way they escape targeted therapy. A tumor cannot delete the fact that its cells have an inside. Every dying cell exposes actin.
The engineered trigger can be edited away. The natural one cannot.
Which makes their discussion strange. It waves off conventional dendritic cell vaccines as "limited by inefficient antigen presentation." The word lysate does not appear in that paper, its methods, or its extended data. They never built the comparator. The claim is a citation to a review, not an experiment they ran.
And they never tested the thing that matters most. No rechallenge. No memory experiment. No cures, no tumor-free animals. Growth delay and survival curves.
Durability is the whole reason to reach for a dendritic cell instead of a T cell product. It is the one thing they left untested.
It is also the thing DCVax-L has been tested on, in people, for years.